Taysha Gene Therapies to Participate in Upcoming April Investor Healthcare Conferences
April 05 2021 - 7:00AM
Business Wire
20th Annual Needham Virtual Healthcare
Conference on Monday, April 12, 2021 at 10:15 am ET
Chardan 5th Annual Manufacturing Summit on
Monday, April 26, 2021 at 1:00 pm ET
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric,
clinical-stage gene therapy company focused on developing and
commercializing AAV-based gene therapies for the treatment of
monogenic diseases of the central nervous system (CNS) in both rare
and large patient populations, today announced its participation in
virtual fireside chats for the 20th Annual Needham Virtual
Healthcare Conference and the Chardan 5th Annual Manufacturing
Summit.
Conferences Details:
Event:
20th Annual Needham Virtual Healthcare
Conference
Date:
Monday, April 12, 2021
Time:
10:15 am ET
Format:
Fireside chat
Participants:
RA Session II, President, Founder and
CEO
Event:
Chardan 5th Annual Manufacturing
Summit
Date:
Monday, April 26, 2021
Time:
1:00 pm ET
Format:
Fireside chat
Participants:
RA Session II, President, Founder and
CEO
Fred Porter, Ph.D., Chief Technical
Officer
Greg Gara, Senior Vice President of
Manufacturing
Webcasts for these conferences will be available in the “Events
& Media” section of the Taysha corporate website at
https://ir.tayshagtx.com/news-events/events-presentations. Archived
versions of the webcasts will be available on the website for 60
days.
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to
eradicate monogenic CNS disease. With a singular focus on
developing curative medicines, we aim to rapidly translate our
treatments from bench to bedside. We have combined our team’s
proven experience in gene therapy drug development and
commercialization with the world-class UT Southwestern Gene Therapy
Program to build an extensive, AAV gene therapy pipeline focused on
both rare and large-market indications. Together, we leverage our
fully integrated platform—an engine for potential new cures—with a
goal of dramatically improving patients’ lives. More information is
available at www.tayshagtx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210405005218/en/
Company Contact: Kimberly Lee, D.O. SVP, Corporate
Communications and Investor Relations Taysha Gene Therapies
klee@tayshagtx.com
Media Contact: Carolyn Hawley Canale Communications
carolyn.hawley@canalecomm.com
Taysha Gene Therapies (NASDAQ:TSHA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Taysha Gene Therapies (NASDAQ:TSHA)
Historical Stock Chart
From Sep 2023 to Sep 2024